ARCHIVES

Phase 0 Trials Signal FDA’s New Reliance On Biomarkers For Drug Development.

This article is from The Cancer Letter archive.

Vol. 32 No. 01 | January 13, 2006

Download PDF Visit The Full Archive

Related Articles

Pfizer’s Withdrawal Of Mylotarg Signals Stronger FDA Resolve To Monitor Confirmatory Studies

June 25, 2010

Nomograms 66% Correct In Predicting Outcome For Brachytherapy, Study Finds

September 28, 2001

ASCO To Include Chernobyl Talk, Educational sessions

May 1, 1987

Prevention Trial Could Stand On Its Own

October 28, 1994

NCI to Undergo More GAO Probes

July 15, 1977

Univ. Of Pittsburgh Plans Molecular Medicine Institute.

January 25, 2002